AbbVie Announces European Commission Approval of AQUIPTA® (atogepant) for the Acute Treatment of Migraine in Adults
AQUIPTA® (atogepant) is now approved in the European Union for the acute treatment of migraine in adults, with or without aura, and for the prophylaxis of migraine in adults who have at least four migraine days per month. Approval was based on the pivotal Phase 3 ECLIPSE trial, which...
AQUIPTA® (atogepant) is now approved in the European Union for the acute treatment of migraine in adults, with or without aura, and for the prophylaxis of migraine in adults who have at least four migraine days per month. Approval was based on the pivotal Phase 3 ECLIPSE trial, which...
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.